search
Back to results

Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee

Primary Purpose

Osteoarthritis, Knee

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
YYD302 2ml
Active comparator: Synovian Inj.
Sponsored by
Yooyoung Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Osteoarthritis

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

[Visit 1, 2 Inclusion Criteria]

  1. Males or Females 40 years and older
  2. According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings.

1) Over 50 years of age 2) Less than 30 minutes of morning stiffness 3) Crepitus on active motion 4) 4 bony tenderness 5) Bony enlargement 6) Nopalpable warmth of synvium 3. Within 6 months from screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination.

4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the single or both sides of the osteoarthritis is over 40mm 5. Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past.

6. Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.) 7. Patient who agrees to participate in this clinical trial by themselves.

[Visit 6, 7 Inclusion criteria] 1. According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings.

  1. Over 50 years of age
  2. Less than 30 minutes of morning stiffness
  3. Crepitus on active motion
  4. 4 bony tenderness
  5. Bony enlargement
  6. Nopalpable warmth of synvium 2. At Re-screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination.

3. Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.) 4. Patient who are confirmed for Responder by efficacy at visit 5.

Exclusion Criteria:

  1. Someone who has BMI≥32kg/m² at the screening visit.
  2. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can have an effect on pain sense over 3 months habitually.
  3. Patient who has been administrated gastrointestinal drug(for example H₂-blockers, misoprostol or proton pump inhibitors) regularly, who can't stop injecting for clinical study period.
  4. Patient has attended abnormal values from screening test(2 times excess at upper limit of the normal values at ALT, AST, BUN, Serum Creatinine).
  5. Patient who has rheumarthritis or other inflammatory metabolic arthritis.
  6. Patients having serious gastrointestinal, liver, renal, heart disease.
  7. When the inflammatory disease is occurred on joint area to patient like septic arthritis.
  8. Patients having skin ailment at the injecting site of the joint region.
  9. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis or systemic disease.
  10. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc herniation.
  11. Poly-articular patients who have suffered seriously by osteoarthritis at other parts affect judge of the knee joint pain.
  12. Patients who diagnosed clear interval disappearance at the knee joint by X-ray.
  13. Patients who were administrated below drugs before baseline visit. 1) Patients who were injected HA at the target knee joint or other parts of knee joint in recent 9 months.

2) Patients who were injected steroids into the intra-articular knee joint in recent 3 months 3) Patients who were administrated steroids systemically by the oral medication (But, except inhalation) 4) Patients who were administerated Osteoarthritis nutrition such as glucosamine/chondroichin sulfate or physical therapy or herbal remedy(acupuncture, yellowish swelling, moxa cautery) for the purpose of pain relief in recent 2 weeks 5) Patients who have administerated steroid/No-steriod NSAIDs or other pain relief drugs (patch or other external medicine) in recents 2 weeks except Acetaminophen or below 300mg/day of Asprin 14. Patients who have joint effusion trouble were judged as a positive by tests like Patella tap test.

15. Patients who have target knee joint gotten surgical operation history including Arthroscopy within past one year (In case of having other side of knee joint or hip joint gotten surgical operation history, excepting the patients if there is possibility which can influence the target knee joint's appraisal.

16. Patients who have an operation history about target knee joint. 17. Patients who do the height weight aerobic exercise or anaerobic exercise. 18. Patients who need to be administrated anticoagulant agent together(But, except 300mg daily dose aspirin) 19. Patients who have hypersensitivity history about Investigational Product.

20. In the midst of women in their childbearing years, patients who disagree to do * contraception by medically permitted method for 12 weeks from administrating investigational product.

  • The contraception by medically permitted method: Condom, In case of using injection or insertion, In case of installing a intrauterine contraception device etc.

    21. Pregnant and lactating women 22. Patients who were injected other investigational product over a time within 30 days before participated in this clinical trail.

    23. Besides that, the patients who have difficulty to be participated in this clinical trial continuously by Principle Investigator (PI)'s decision.

  • Exclusion criteria for Re-injection is except for 13-1) Re-injection date is followed by visit 7.

Sites / Locations

  • Samsung Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

YYD302

Synovian Inj.

Arm Description

YYD302 (2ml)

Synovian Inj. (3ml)

Outcomes

Primary Outcome Measures

Rate of change of the Weight-bearing pain(100mm-VAS) on 12 weeks after first injection in comparison with baseline
Weight-bearing pain(100mm-VAS) assessed by the subject

Secondary Outcome Measures

Rate of change of the Weight-bearing pain(100mm-VAS) on 2, 4 weeks after administration in comparison with baseline
Weight-bearing pain(100mm-VAS) assessed by the subject
Rate of change of the KOOS scales on the 2, 4, 12 weeks after administration in comparison with baseline
KOOS scales assessed by the subject
Rate of change of the rest pain(100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline
Rest pain(100mm-VAS) assessed by the subject
Rate of change of the Motion pain (100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline
Motion pain(100mm-VAS) assessed by the subject
Patient global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline
Patient global assessment (100mm-VAS) assessed by the subject
Investigator global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline
Patient global assessment (100mm-VAS) assessed by the investigator
Change of the swelling in the knee joint from baseline to 2, 4, 12 weeks after administration
Sweeling assessed by the investigator
Change of the tenderness on pressure in the knee joint from baseline to 2, 4, 12 weeks after administration
Tenderness on pressure assessed by the investigator
Variation of the Range Of Motion(ROM) in the knee joint on 2, 4, 12 weeks after administration with baseline
Range of motion assessed by the investigator
Responder rate of the Weight-bearing pain on 12 weeks in comparison with baseline
Responder rate of the Weight-bearing pain assessed by the investigator
Responder rate of the OMERACT-OARSI on 12 weeks in comparison with baseline
Responder rate of the OMERACT-OARSI assessed by the investigator
Use of rescue medication count and the total amount on each visit after injection
Use of rescue medication count and the total amount assessed by subject
The efficacy of secondary outcome 1~11 after 12 weeks(36weeks) compared with the Re-injection(24weeks) in re-injection subjects
Each outcome assessed by the investigator or subject
The efficacy of secondary outcome 1~11 after baseline compared with 2, 4, 12, 24, 36 weeks in Re-injection subjects
Each outcome assessed by the investigator or subject

Full Information

First Posted
June 4, 2018
Last Updated
May 7, 2021
Sponsor
Yooyoung Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03561779
Brief Title
Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee
Official Title
A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Study to Evaluated the Safety and Efficacy of Intraarticular Hyalurinic Acid(YYD302) for Osteoarthritis of the Knee After 12 Weeks of Treatment and Retreatment
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
February 21, 2018 (Actual)
Primary Completion Date
June 14, 2019 (Actual)
Study Completion Date
October 4, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yooyoung Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized, double-blind, active-controlled, multi-center, phase 3 study to evaluate the safety and efficacy of intraarticular hyaluronic acid(YYD302) for osteoarthritis of the knee after 12 weeks of treatment and retreatment
Detailed Description
First Injection: A multicenter, active-controlled, randomized, evaluator and subject bllinded, parallel, phase 3 study Re-Injection: A multicenter, active-controlled, randomized, parallel

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee
Keywords
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
The Subjects are injected investigational Product (YYD302 or Synovian Inj.)
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
184 (Actual)

8. Arms, Groups, and Interventions

Arm Title
YYD302
Arm Type
Experimental
Arm Description
YYD302 (2ml)
Arm Title
Synovian Inj.
Arm Type
Active Comparator
Arm Description
Synovian Inj. (3ml)
Intervention Type
Drug
Intervention Name(s)
YYD302 2ml
Intervention Description
YYD302 2ml
Intervention Type
Drug
Intervention Name(s)
Active comparator: Synovian Inj.
Other Intervention Name(s)
Synovian Inj.
Intervention Description
Active comparator: Synovian Inj.
Primary Outcome Measure Information:
Title
Rate of change of the Weight-bearing pain(100mm-VAS) on 12 weeks after first injection in comparison with baseline
Description
Weight-bearing pain(100mm-VAS) assessed by the subject
Time Frame
Change of the week 12 from baseline
Secondary Outcome Measure Information:
Title
Rate of change of the Weight-bearing pain(100mm-VAS) on 2, 4 weeks after administration in comparison with baseline
Description
Weight-bearing pain(100mm-VAS) assessed by the subject
Time Frame
Change of the week 2, 4 from baseline
Title
Rate of change of the KOOS scales on the 2, 4, 12 weeks after administration in comparison with baseline
Description
KOOS scales assessed by the subject
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Rate of change of the rest pain(100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline
Description
Rest pain(100mm-VAS) assessed by the subject
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Rate of change of the Motion pain (100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline
Description
Motion pain(100mm-VAS) assessed by the subject
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Patient global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline
Description
Patient global assessment (100mm-VAS) assessed by the subject
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Investigator global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline
Description
Patient global assessment (100mm-VAS) assessed by the investigator
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Change of the swelling in the knee joint from baseline to 2, 4, 12 weeks after administration
Description
Sweeling assessed by the investigator
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Change of the tenderness on pressure in the knee joint from baseline to 2, 4, 12 weeks after administration
Description
Tenderness on pressure assessed by the investigator
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Variation of the Range Of Motion(ROM) in the knee joint on 2, 4, 12 weeks after administration with baseline
Description
Range of motion assessed by the investigator
Time Frame
Change of the week 2, 4, 12 from baseline
Title
Responder rate of the Weight-bearing pain on 12 weeks in comparison with baseline
Description
Responder rate of the Weight-bearing pain assessed by the investigator
Time Frame
Change of the week 12 from baseline
Title
Responder rate of the OMERACT-OARSI on 12 weeks in comparison with baseline
Description
Responder rate of the OMERACT-OARSI assessed by the investigator
Time Frame
Change of the week 12 from baseline
Title
Use of rescue medication count and the total amount on each visit after injection
Description
Use of rescue medication count and the total amount assessed by subject
Time Frame
Change of the each visit(2, 4, 12, 24, 36 weeks) after injection
Title
The efficacy of secondary outcome 1~11 after 12 weeks(36weeks) compared with the Re-injection(24weeks) in re-injection subjects
Description
Each outcome assessed by the investigator or subject
Time Frame
Change of the week 12 (36 weeks) after Re-injection(24weeks)
Title
The efficacy of secondary outcome 1~11 after baseline compared with 2, 4, 12, 24, 36 weeks in Re-injection subjects
Description
Each outcome assessed by the investigator or subject
Time Frame
Change of the week 2, 4, 12, 24, 36 from baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: [Visit 1, 2 Inclusion Criteria] Males or Females 40 years and older According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings. 1) Over 50 years of age 2) Less than 30 minutes of morning stiffness 3) Crepitus on active motion 4) 4 bony tenderness 5) Bony enlargement 6) Nopalpable warmth of synvium 3. Within 6 months from screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination. 4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the single or both sides of the osteoarthritis is over 40mm 5. Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past. 6. Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.) 7. Patient who agrees to participate in this clinical trial by themselves. [Visit 6, 7 Inclusion criteria] 1. According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings. Over 50 years of age Less than 30 minutes of morning stiffness Crepitus on active motion 4 bony tenderness Bony enlargement Nopalpable warmth of synvium 2. At Re-screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination. 3. Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.) 4. Patient who are confirmed for Responder by efficacy at visit 5. Exclusion Criteria: Someone who has BMI≥32kg/m² at the screening visit. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can have an effect on pain sense over 3 months habitually. Patient who has been administrated gastrointestinal drug(for example H₂-blockers, misoprostol or proton pump inhibitors) regularly, who can't stop injecting for clinical study period. Patient has attended abnormal values from screening test(2 times excess at upper limit of the normal values at ALT, AST, BUN, Serum Creatinine). Patient who has rheumarthritis or other inflammatory metabolic arthritis. Patients having serious gastrointestinal, liver, renal, heart disease. When the inflammatory disease is occurred on joint area to patient like septic arthritis. Patients having skin ailment at the injecting site of the joint region. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis or systemic disease. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc herniation. Poly-articular patients who have suffered seriously by osteoarthritis at other parts affect judge of the knee joint pain. Patients who diagnosed clear interval disappearance at the knee joint by X-ray. Patients who were administrated below drugs before baseline visit. 1) Patients who were injected HA at the target knee joint or other parts of knee joint in recent 9 months. 2) Patients who were injected steroids into the intra-articular knee joint in recent 3 months 3) Patients who were administrated steroids systemically by the oral medication (But, except inhalation) 4) Patients who were administerated Osteoarthritis nutrition such as glucosamine/chondroichin sulfate or physical therapy or herbal remedy(acupuncture, yellowish swelling, moxa cautery) for the purpose of pain relief in recent 2 weeks 5) Patients who have administerated steroid/No-steriod NSAIDs or other pain relief drugs (patch or other external medicine) in recents 2 weeks except Acetaminophen or below 300mg/day of Asprin 14. Patients who have joint effusion trouble were judged as a positive by tests like Patella tap test. 15. Patients who have target knee joint gotten surgical operation history including Arthroscopy within past one year (In case of having other side of knee joint or hip joint gotten surgical operation history, excepting the patients if there is possibility which can influence the target knee joint's appraisal. 16. Patients who have an operation history about target knee joint. 17. Patients who do the height weight aerobic exercise or anaerobic exercise. 18. Patients who need to be administrated anticoagulant agent together(But, except 300mg daily dose aspirin) 19. Patients who have hypersensitivity history about Investigational Product. 20. In the midst of women in their childbearing years, patients who disagree to do * contraception by medically permitted method for 12 weeks from administrating investigational product. The contraception by medically permitted method: Condom, In case of using injection or insertion, In case of installing a intrauterine contraception device etc. 21. Pregnant and lactating women 22. Patients who were injected other investigational product over a time within 30 days before participated in this clinical trail. 23. Besides that, the patients who have difficulty to be participated in this clinical trial continuously by Principle Investigator (PI)'s decision. Exclusion criteria for Re-injection is except for 13-1) Re-injection date is followed by visit 7.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chul-Won Ha, M.D
Organizational Affiliation
Samsung Medical Center, Department of Internal Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34736768
Citation
Park YG, Ha CW, Yoo JH, Lee WS, Lee HJ, In Y, Bae KC, Shon OJ, Kim YM, Seon JK, Song SJ, Chang CB, Kim JM, Kim CW, Kim DH, Bae JH. Intra-Articular Injection of a Novel DVS Cross-Linked Hyaluronic Acid Manufactured by Biological Fermentation (YYD302) in Patients With Knee Osteoarthritis: A Double-Blind, Randomized, Multicenter, Noninferiority Study. Clin Ther. 2021 Nov;43(11):1843-1860. doi: 10.1016/j.clinthera.2021.09.005. Epub 2021 Nov 1.
Results Reference
derived

Learn more about this trial

Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee

We'll reach out to this number within 24 hrs